External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Growth Driven by Base Business: Aurobindo reported revenue of Rs 8,286 Cr in Q2FY26, broadly in line with expectations.</li><li>Revenue grew 6.3% YoY and 5.3% QoQ, supported by strong performance in its core base business.</li><li>Consolidated growth was maintained despite limited contribution from Revlimid, which is expected to taper off entirely from Q3 onwards.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Growth Driven by Base Business: Aurobindo reported revenue of Rs 8,286 Cr in Q2FY26, broadly in line with expectations.Revenue grew 6.3% YoY and 5.3% QoQ, supported by strong performance in its core base business.Consolidated growth was maintained despite limited contribution from Revlimid, which is expected to taper off entirely from Q3 onwards.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aurobindo Pharma Ltd - Base Business Sustaining Momentum